X4制药 XFOR 深 沪
等待开盘 07-06 09:30:00 美东时间
4.13
+0.045
+1.10%
华盛通- 最 高4.305
- 今 开4.15
- 成交量 67.89万股
- 最 低 4.08
- 昨 收 4.085
- 总市值 3.90亿
- 52周最高 4.83
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 1.35
- 委 比 61.58%
- 总股本 9431.97万
- 历史最高 717.90
- 量 比 0.25
- 振 幅 5.51%
- 历史最低 2.83
- 每 手 1
- 风险率 0.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
X4 Pharmaceuticals announced the appointment of Kelly Gold to its Board of Directors effective July 1, 2026. Ms. Gold, an independent director and member of the Audit Committee, brings extensive financial and biotech expertise. She currently serves as CFO at CAMP4 Therapeutics and previously held senior roles at Biogen and Deutsche Bank. Gold holds degrees in Biochemistry, Mechanical Engineering, and an MBA from MIT. X4 focuses on developing ther...
07-01 11:00
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
X4 Pharmaceuticals announced that its management will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 3:45 p.m. ET. A live and archived webcast will be available on the company's website under the Investors section. X4 is focused on improving lives of people with rare hematology diseases and has developed mavorixafor, an approved therapy for WHIM syndrome. The company is currently conducting a Phase 3 clinical trial...
05-27 11:00
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 500 percent decrease over earnings of $0.04 per share from the
05-06 19:51
X4 Pharma Says EC Grants Marketing Authorization For XOLREMDI Capsules For Treatment Of Patients With WHIM Syndrome In EU
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia -BOSTON, April 29, 2026 (GLOBE
04-29 19:14
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals issued inducement awards to new employees, totaling 32,000 stock options, under the 2019 Inducement Plan, approved by its Compensation Committee. The options have a $4.13 exercise price, a 10-year term, and vest over four years, with 25% after 12 months and the remainder monthly over 36 months. X4, based in Boston, focuses on treating rare hematologic diseases and is advancing mavorixafor, which has received FDA Fast Track desi...
04-01 20:30
X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice
X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice X4 Pharmaceuticals will hold its annual meeting virtually on May 11, 2026. Shareholders will vote to elect three Class III director nominees to serve until the 2029 annual meeting. The meeting agenda also includes ratifying Pricewa
03-20 20:46
Rare disease drugmaker X4 Pharma's Q4 revenue rises on XOLREMDI strength
Rare disease drugmaker X4 Pharma's Q4 revenue rises on XOLREMDI strength Overview Rare hematology drug developer's Q4 revenue reached $2.6 mln, driven by XOLREMDI sales and licensing Company posted Q4 net loss of $23.9 mln, or $0.22 per share Cash runway projected through 2028 after equity financing
03-17 19:29
X4 Pharmaceuticals Q4 EPS $(0.22) Beats $(0.38) Estimate, Sales $2.568M Beat $1.733M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 96.26 percent increase over losses of $(5.89) per share
03-17 19:18
